Additionally, the 36-month beta value for INTS is 4.34. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for INTS is 10.02M and currently, short sellers hold a 4.61% ratio of that float. The average trading volume of INTS on June 18, 2025 was 958.88K shares.
INTS) stock’s latest price update
Intensity Therapeutics Inc (NASDAQ: INTS)’s stock price has soared by 10.21 in relation to previous closing price of 0.29. Nevertheless, the company has seen a loss of -45.58% in its stock price over the last five trading days. prnewswire.com reported 2025-06-11 that SHELTON, Conn., June 11, 2025 /PRNewswire/ — Intensity Therapeutics, Inc. (Nasdaq: INTS) (“Intensity” or the “Company”), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the pricing of its underwritten public offering of 6,675,000 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of $2,002,500, before deducting underwriting discounts, commissions and offering expenses.
INTS’s Market Performance
Intensity Therapeutics Inc (INTS) has experienced a -45.58% fall in stock performance for the past week, with a -21.44% drop in the past month, and a -83.42% drop in the past quarter. The volatility ratio for the week is 27.87%, and the volatility levels for the past 30 days are at 17.32% for INTS. The simple moving average for the past 20 days is -22.67% for INTS’s stock, with a -86.10% simple moving average for the past 200 days.
INTS Trading at -59.62% from the 50-Day Moving Average
After a stumble in the market that brought INTS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.82% of loss for the given period.
Stock Fundamentals for INTS
The total capital return value is set at -34.94. Equity return is now at value -298.57, with -194.04 for asset returns.
Based on Intensity Therapeutics Inc (INTS), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at -98.04.
Currently, EBITDA for the company is -16.24 million with net debt to EBITDA at 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.63.
Conclusion
In conclusion, Intensity Therapeutics Inc (INTS) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
